Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&eacut...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fd36db5f774b4124b36b99645b5e827a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fd36db5f774b4124b36b99645b5e827a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fd36db5f774b4124b36b99645b5e827a2021-12-02T06:11:12ZActivation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment1179-9889https://doaj.org/article/fd36db5f774b4124b36b99645b5e827a2015-07-01T00:00:00Zhttp://www.dovepress.com/activation-of-wild-type-p53-by-mdm2-inhibitors-a-new-strategy-for-lymp-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Créteil, 3Inserm U955, Institut Mondor de Recherche Biomédicale, 4UMR 8126 CNRS, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France*These authors contributed equally to this workAbstract: The tumor suppressor TP53 is frequently mutated or inactivated in human cancers. Mutations of TP53 are less common in lymphomas than in other tumors, but the protein is often inhibited by the overexpression of its main regulator – MDM2. In the past 10 years, major efforts have been made to develop drugs that can reactivate p53 and restore its functions. This review focuses on recent advances in the development of small inhibitors of MDM2, which are potentially relevant for the treatment of B- and T-cell lymphomas. We will describe the current state of development of these drugs and discuss their mechanism of action in these hematological malignancies.Keywords: lymphoma, p53, nutlin, apoptosis, MDM2Pujals AFavre LGaulard PWiels JDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 93-100 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Diseases of the blood and blood-forming organs RC633-647.5 Pujals A Favre L Gaulard P Wiels J Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| description |
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Créteil, 3Inserm U955, Institut Mondor de Recherche Biomédicale, 4UMR 8126 CNRS, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France*These authors contributed equally to this workAbstract: The tumor suppressor TP53 is frequently mutated or inactivated in human cancers. Mutations of TP53 are less common in lymphomas than in other tumors, but the protein is often inhibited by the overexpression of its main regulator – MDM2. In the past 10 years, major efforts have been made to develop drugs that can reactivate p53 and restore its functions. This review focuses on recent advances in the development of small inhibitors of MDM2, which are potentially relevant for the treatment of B- and T-cell lymphomas. We will describe the current state of development of these drugs and discuss their mechanism of action in these hematological malignancies.Keywords: lymphoma, p53, nutlin, apoptosis, MDM2 |
| format |
article |
| author |
Pujals A Favre L Gaulard P Wiels J |
| author_facet |
Pujals A Favre L Gaulard P Wiels J |
| author_sort |
Pujals A |
| title |
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| title_short |
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| title_full |
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| title_fullStr |
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| title_full_unstemmed |
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment |
| title_sort |
activation of wild-type p53 by mdm2 inhibitors: a new strategy for lymphoma treatment |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/fd36db5f774b4124b36b99645b5e827a |
| work_keys_str_mv |
AT pujalsa activationofwildtypep53bymdm2inhibitorsanewstrategyforlymphomatreatment AT favrel activationofwildtypep53bymdm2inhibitorsanewstrategyforlymphomatreatment AT gaulardp activationofwildtypep53bymdm2inhibitorsanewstrategyforlymphomatreatment AT wielsj activationofwildtypep53bymdm2inhibitorsanewstrategyforlymphomatreatment |
| _version_ |
1718400089581420544 |